U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07510646) titled 'Transcranial Photobiomodulation for Bipolar Depression' on March 16, 2025.
Brief Summary: This study the effectiveness and safety of light therapy device targeted at the brain using a wearable device, the Vielight RX Gamma as a treatment for bipolar depression. Up to forty patients with bipolar disorder will be enrolled into the study and will either receive active treatment with the Vielight RX Gamma or sham (inactive device). They will be administered the devices in clinic 5days/week for 6 weeks. Changes in disease symptoms, cognitive function, pain, quality of life and rest EEG changes will be assessed.
Study Start Date: July 01...